We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

1 hedge funds and large institutions have $68 invested in Global Blood Therapeutics, Inc. in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more capital invested

Capital invested by funds: $68 → $68 ($0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HNB
1
Huntington National Bank
Ohio
$68 – – –

GBT Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2023, worth a combined $68 — unchanged from a quarter earlier.

Fund positioning in GBT was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Global Blood Therapeutics, Inc. (GBT) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $68 of Global Blood Therapeutics, Inc. stock for Q2 2023, unchanged quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2023 and 0 closed out.

Based on aggregated 13F filings for Q2 2023.